T1	Participants 0 127	Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer
T2	Participants 464 517	patients with hormone-receptor-positive breast cancer
T3	Participants 527 588	We did this phase 2 trial in outpatient clinics and hospitals
T4	Participants 602 742	postmenopausal women with hormone-receptor-positive, locally advanced or metastatic breast cancer previously treated with endocrine treatmen
T5	Participants 750 1062	were randomly assigned (2:1) with a central randomisation schedule to receive intravenous ganitumab 12 mg per kg bodyweight or placebo in combination with open-label intramuscular fulvestrant (500 mg on day 1, then 250 mg on days 15, 29, and every 28 days) or oral exemestane (25 mg once daily) on a 28-day cycle
T6	Participants 1437 1535	We screened 189 patients and enrolled 156 (106 in the ganitumab group and 50 in the placebo group)
T7	Participants 1870 1960	With the exception of hyperglycaemia, adverse events were generally similar between groups
